Main content

The use of Thrombospondin-1 Mimetic Peptides for the Treatment of Epithelial Ovarian Cancer

Show simple item record

dc.contributor.advisor Petrik, Jim
dc.contributor.author Campbell, Nicole
dc.date.accessioned 2012-05-07T16:45:35Z
dc.date.available 2012-05-07T16:45:35Z
dc.date.copyright 2012-04
dc.date.created 2012-04-19
dc.date.issued 2012-05-07
dc.identifier.uri http://hdl.handle.net/10214/3571
dc.description.abstract This thesis is an investigation of the use of thrombospondin-1 mimetic peptides for the treatment of epithelial ovarian cancer. The current standard of care for women diagnosed with ovarian cancer is surgical de-bulking followed by chemotherapeutics. Initially, this treatment regimen results in a reduction in the primary tumor, unfortunately chemoresistance and disease recurrence are problematic. Recent data has suggested a potential role for anti-angiogenic therapy for the treatment of various cancers. Therefore, the purpose of this study was to investigate the use of mimetics consisting of the anti-angiogenic domain of thrombospondin-1 (TSP-1) for the treatment of epithelial ovarian cancer (EOC) using a mouse model of the disease. The peptides were applied at various stages of tumor progression and a significant reduction in tumor size following treatment was observed. We found that not only were the peptides capable of slowing down tumor progression but they also played a role in reducing the size of established tumors. Treatment with TSP-1 mimetics also resulted in a significant reduction in secondary lesions and ascites fluid in the peritoneal cavity of animals. A significant increase in disease-free survival was also identified following long-term treatment with the peptide. Various histological studies revealed that the anti-angiogenic peptide was in fact inducing apoptosis of the endothelial cells and also re-organizing the vasculature. To determine whether this resulted in increased blood vessel profusion we applied standard chemotherapeutics in combination with TSP-1 mimetics. Experiments with radiolabelled and fluorescent chemotherapeutics demonstrated that pre-treating with TSP-1 mimetics allowed the vasculature to become normalized and resulted in an increased uptake of chemotherapeutics. Lastly, we investigated the mechanism of action of anti-angiogenic peptides. Most of the anti-tumor effects appeared to be due to the apoptotic effects of TSP-1 mimetics on the vasculature. A direct apoptotic effect on epithelial cells also was observed; however, it is uncertain how much of a role this plays. In conclusion, this study was important for identifying TSP-1 mimetic peptides as a potential therapeutic treatment for women suffering from EOC. en_US
dc.language.iso en en_US
dc.subject ovarian cancer en_US
dc.subject angiogenesis en_US
dc.subject thrombospondin-1 en_US
dc.subject therapeutics en_US
dc.title The use of Thrombospondin-1 Mimetic Peptides for the Treatment of Epithelial Ovarian Cancer en_US
dc.type Thesis en_US
dc.degree.programme Biomedical Sciences en_US
dc.degree.name Doctor of Philosophy en_US
dc.degree.department Department of Biomedical Sciences en_US
dc.rights.license All items in the Atrium are protected by copyright with all rights reserved unless otherwise indicated.


Files in this item

Files Size Format View
Thesis-_N.Campbell_May2.pdf 3.604Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record